Stocks · Health care · Surgical & Medical Instruments & Apparatus

RenovoRx, Inc.

RNXT Clue Score55
United States Fiscal year ends December CIK 0001574094
$1.28 -3.76% Close, 9 Oct 2026
Price $1.28 −76.73% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 26 Aug 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Operating income−3.2Net income−3.8Fiscal year 2021Operating income−5.7Net income−6.3Fiscal year 2022Operating income−10.0Net income−9.9EPS, diluted−1.09Fiscal year 2023Operating income−11.4Net income−10.2EPS, diluted−0.99Fiscal year 2024Revenue0.0Operating income−11.0Net income−8.8EPS, diluted−0.40Fiscal year 2025Revenue1.1 +2,511.6%Operating income−12.5Net income−11.2EPS, diluted−0.32
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a 0.0 1.1
Growth +2,511.6%
Operating income −3.2 −5.7 −10.0 −11.4 −11.0 −12.5
Net income −3.8 −6.3 −9.9 −10.2 −8.8 −11.2
Growth
EPS, diluted n/a n/a −1.09 −0.99 −0.40 −0.32

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Gross margin100.0%Operating margin−25,511.6%Net margin−20,497.7%Free cash flow margin−21,248.8%Fiscal year 2025Gross margin70.9%Operating margin−1,114.0%Net margin−994.5%Free cash flow margin−977.3%
FY2020FY2021FY2022FY2023FY2024FY2025
Gross margin n/a n/a n/a n/a 100.0% 70.9%
Operating margin n/a n/a n/a n/a −25,511.6% −1,114.0%
Net margin n/a n/a n/a n/a −20,497.7% −994.5%
Free cash flow margin n/a n/a n/a n/a −21,248.8% −977.3%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−3.5Fiscal year 2021Operating cash flow−5.9Fiscal year 2022Operating cash flow−8.8Fiscal year 2023Operating cash flow−10.3Fiscal year 2024Operating cash flow−9.1Capital expenditure−0.0Free cash flow−9.1Fiscal year 2025Operating cash flow−11.0Capital expenditure−0.0Free cash flow−11.0
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −3.5 −5.9 −8.8 −10.3 −9.1 −11.0
Capital expenditure n/a n/a n/a n/a −0.0 −0.0
Free cash flow n/a n/a n/a n/a −9.1 −11.0
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash1.8Shareholders’ equity−14.7Fiscal year 2021Cash15.2Shareholders’ equity15.3Fiscal year 2022Cash4.4Shareholders’ equity6.2Fiscal year 2023Cash1.2Shareholders’ equity3.0Fiscal year 2024Cash7.2Shareholders’ equity4.5Fiscal year 2025Cash7.0Shareholders’ equity5.4
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 1.8 15.2 4.4 1.2 7.2 7.0
Shareholders’ equity −14.7 15.3 6.2 3.0 4.5 5.4

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Operations
−3.5 −5.9 −8.8 −10.3 −9.1 −11.0
Growth
Investment
n/a n/a n/a n/a −0.0 −0.0
calc n/a n/a n/a n/a −9.1 −11.0
Growth
calc n/a n/a n/a n/a −0.41 −0.31
n/a −0.0 −2.0 2.0 −0.0 −0.0
Financing
3.2 19.3 0.0 5.0 15.1 10.8

† The diluted share count jumps at 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.